ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.68
0.00%
US Tech 100
17,015.60
0.92%
S&P 500
5,018.39
-0.34%
US Dollar vs CAD
1.37193
-0.03%
Bitcoin
58,835.10
1.03%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AcelRX Pharmaceuticals Inc (ACRX)

  7. AcelRX Pharmaceuticals Inc (ACRX) News

ACRX AcelRX Pharmaceuticals Inc

0.86
0.00 (0.00%)
Pre Market
Last Updated: 19:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
AcelRX Pharmaceuticals Inc ACRX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 0.86 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.86
more quote information »

Recent News

Date Time Source Heading
4/29/202415:25EDGAR2Form ARS - Annual Report to Security Holders
4/29/202415:24EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
4/29/202415:23EDGAR2Form DEF 14A - Other definitive proxy statements
4/19/202415:37EDGAR2Form 8-K - Current report
3/21/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/15/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/12/202417:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/09/202408:17EDGAR2Form 8-K - Current report
1/09/202408:05PRNUSAcelRx Announces Rebranding With Name Change to Talphera,..
12/14/202307:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/13/202315:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/13/202315:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202307:30PRNUSAcelRx Pharmaceuticals Announces Publication of Study..
11/22/202315:38EDGAR2Form S-3 - Registration statement under Securities Act of..
11/22/202315:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/14/202305:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/08/202315:14EDGAR2Form 8-K - Current report
11/08/202315:05PRNUSAcelRx Reports Third Quarter 2023 Financial Results and..
11/07/202315:05PRNUSAcelRx to Host KOL Panel Discussion on Current Anticoagulant..
10/26/202315:30PRNUSAcelRx to Host Third Quarter 2023 Financial Results Call and..
10/20/202315:30EDGAR2Form 8-K - Current report
10/10/202315:17EDGAR2Form 8-K - Current report
10/05/202315:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/05/202315:30EDGAR2Form 8-K - Current report
10/03/202307:30PRNUSAcelRx Receives IDE Approval for Niyad and Advances to a..
9/22/202316:18EDGAR2Form 8-K - Current report
9/11/202318:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/06/202307:30PRNUSAcelRx Pharmaceuticals to Participate in the H.C. Wainwright..
8/28/202305:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
8/28/202305:34EDGAR2Form DEF 14A - Other definitive proxy statements
8/25/202315:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/25/202311:45EDGAR2Form 144 - Report of proposed sale of securities
8/24/202315:23EDGAR2Form 144 - Report of proposed sale of securities
8/10/202316:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/10/202315:10EDGAR2Form 8-K - Current report
8/10/202315:05PRNUSAcelRx Reports Second Quarter 2023 Financial Results and..
8/09/202316:29EDGAR2Form 424B7 - Prospectus [Rule 424(b)(7)]
8/02/202305:06EDGAR2Form S-3 - Registration statement under Securities Act of..
7/27/202315:05PRNUSAcelRx to Host Second Quarter 2023 Financial Results Call..
7/21/202307:15EDGAR2Form 8-K - Current report
7/21/202307:00PRNUSAcelRx Pharmaceuticals Announces Closing of Previously..
7/18/202307:00PRNUSAcelRx Pharmaceuticals Announces $10 Million Private..
5/10/202315:05PRNUSAcelRx Pharmaceuticals Reports First Quarter 2023 Financial..

Your Recent History

NASDAQ
ACRX
AcelRX Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved